诺华实验性抗体Ianalumab在3期试验中达到目标，股价小幅上涨

英为财情

2025/08/12

Investing.com - 诺华 (NYSE:NVS) (SIX:NOVN)表示，其实验性抗体ianalumab与eltrombopag联合使用，在针对原发性免疫性血小板减少症(ITP)患者的3期(VAYHIT2)研究中达到了主要目标。该治疗方案显著延长了治疗失败的时间，测量患者在治疗期间和治疗后维持安全血小板水平的持续时间。诺华股价在欧洲交易中上涨0.5%。这家瑞士制药商表示，这项后期...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2558612945"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2558612945\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2558612945?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-08-12 16:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2558612945","market":"sh","top_or_hot":-1,"title":"诺华实验性抗体Ianalumab在3期试验中达到目标，股价小幅上涨","media":"英为财情","content":"<div>\n<p>Investing.com - 诺华 (NYSE:NVS) (SIX:NOVN)表示，其实验性抗体ianalumab与eltrombopag联合使用，在针对原发性免疫性血小板减少症(ITP)患者的3期(VAYHIT2)研究中达到了主要目标。\n该治疗方案显著延长了治疗失败的时间，测量患者在治疗期间和治疗后维持安全血小板水平的持续时间。\n诺华股价在欧洲交易中上涨0.5%。\n这家瑞士制药商表示，这项后期...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-2932554\">网页链接</a>\n\n</div>\n","source":"investing_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺华实验性抗体Ianalumab在3期试验中达到目标，股价小幅上涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺华实验性抗体Ianalumab在3期试验中达到目标，股价小幅上涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-12 16:00 北京时间&nbsp;&nbsp;&nbsp;<a href=https://cn.investing.com/news/stock-market-news/article-2932554><strong>英为财情</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com - 诺华 (NYSE:NVS) (SIX:NOVN)表示，其实验性抗体ianalumab与eltrombopag联合使用，在针对原发性免疫性血小板减少症(ITP)患者的3期(VAYHIT2)研究中达到了主要目标。\n该治疗方案显著延长了治疗失败的时间，测量患者在治疗期间和治疗后维持安全血小板水平的持续时间。\n诺华股价在欧洲交易中上涨0.5%。\n这家瑞士制药商表示，这项后期...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-2932554\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJT1NW94.SGD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","start_time":0,"source_url":"https://cn.investing.com/news/stock-market-news/article-2932554","article_id":"2558612945","we_media_id":null,"thumbnails":[],"rights":{"source":"investing_news","url":"https://cn.investing.com/news/stock-market-news/article-2932554","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2558612945","pubTimestamp":1754985600,"columns":[],"sourceInfo":{"source_id":"investing_news","name":"英为财情新闻"},"weMediaInfo":null,"summary":"Investing.com - 诺华  表示，其实验性抗体ianalumab与eltrombopag联合使用，在针对原发性免疫性血小板减少症患者的3期研究中达到了主要目标。诺华股价在欧洲交易中上涨0.5%。这家瑞士制药商表示，这项后期试验涉及先前接受过皮质类固醇治疗的ITP患者，结果显示ianalumab还延长了治疗期后安全血小板计数的持续时间。Ianalumab正被研究作为多种自身免疫疾病的潜在疗法。如果获得批准，ianalumab可能成为干燥综合征患者的首个靶向治疗药物。","collect":0,"end_time":0,"defaultTopTitle":"investing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4007":"制药","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","BK4578":"CAR-T","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","NVS":"诺华"},"translate_title":"Novartis's experimental antibody Ianalumab hits target in phase 3 trial, shares edge up","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":1},"content_text":"Investing.com - 诺华 (NYSE:NVS) (SIX:NOVN)表示，其实验性抗体ianalumab与eltrombopag联合使用，在针对原发性免疫性血小板减少症(ITP)患者的3期(VAYHIT2)研究中达到了主要目标。\n该治疗方案显著延长了治疗失败的时间，测量患者在治疗期间和治疗后维持安全血小板水平的持续时间。\n诺华股价在欧洲交易中上涨0.5%。\n这家瑞士制药商表示，这项后期试验涉及先前接受过皮质类固醇治疗的ITP患者，结果显示ianalumab还延长了治疗期后安全血小板计数的持续时间。\nITP是一种罕见的自身免疫疾病，患者的免疫系统会破坏血小板，而血小板是凝血所必需的血细胞。\n根据诺华的数据，该研究还达到了一个关键的次要终点，患者表现出明显更高的持续血小板计数改善率。\n该公司计划在即将举行的医学会议上展示研究结果，并将这些数据纳入计划于2027年提交的监管申请中。\n\"虽然目前治疗ITP的方法通常能有效提高血小板计数，但许多患者需要终身治疗以维持安全水平，这可能造成持续的治疗负担，\"宾夕法尼亚大学医学教授兼血液科主任Adam Cuker表示。\n\"VAYHIT2的结果令人鼓舞，因为它们表明ianalumab可能支持更长时间的疾病控制，并减少持续治疗的需求。\"\nIanalumab正被研究作为多种自身免疫疾病的潜在疗法。\n周一，诺华报告称，该药物在两项针对干燥综合征的3期试验中也达到了主要终点。\n该药物已获得美国食品和药物管理局授予的快速通道资格，诺华表示将向全球监管机构寻求批准。\n如果获得批准，ianalumab可能成为干燥综合征患者的首个靶向治疗药物。\n杰富瑞(Jefferies)分析师在一份报告中表示：\"总体而言，我们认为需要详细数据才能全面评估所观察到的疗效益处的强度。\"\n本文由人工智能协助翻译。更多信息，请参见我们的使用条款。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}